Abstract:Background and objectiveThe individual dosing of drugs that are mainly eliminated unchanged in the urine is made possible by assessing renal function. Most of the methods used are based on serum creatinine (SCr) levels. Cystatin C(CysC) has been proposed as an alternative endogenous marker of the glomerular filtration rate (GFR). Carboplatin is one of the drugs for which elimination is most dependent on the GFR. A prospective clinical trial including 45 patients was conducted to assess the value of serum CysC as a predictor of carboplatin clearance (CL).MethodsThe patients were receiving carboplatin as part of established protocols. Carboplatin was administered as a daily 60-minute infusion at doses ranging from 290 to 1700mg. A population pharmacokinetic analysis was performed using the nonlinear mixed effect modelling NONMEM program according to a two-compartment pharmacokinetic model.ResultsData from 30 patients were used to test the relationships between carboplatin CL and morphological, biological and demographic covariates previously proposed for prediction of the GFR. The interindividual variability of carboplatin CL decreased from 31% (no covariate) to 14% by taking into account five covariates (SCr, CysC, bodyweight [BW], age and sex). Prospective evaluation of these relationships using the data from the other 15 patients confirmed that the best equation to predict carboplatin CL was based on these five covariates, with a mean absolute percentage error of 13% as an assessment of precision. NONMEM analysis of the whole dataset (n = 45 patients) was performed. The best covariate equation corresponding to the overall analysis was: CL (mL/min) = 110 · (SCr/75)−0.512 · (CysC/1.0)−0.327 · (BW/65)0.474 · (age/ 56)−0.387 · 0.854sex, with SCr in μmol/L, CysC in mg/L, BW in kilograms, age in years and sex = 0 if male and 1 if female. To put the value of CysC as an endogenous marker of the GFR into perspective, covariate equations without SCr were also evaluated; a better prediction was obtained by considering CysC together with age and BW (interindividual variability of 16.6% vs 23.3% for CysC alone).ConclusionCysC is a marker of drug elimination that is at least as good as SCr for predicting carboplatin CL. The model based on five covariates was superior to those based on only four covariates (with BW, age and sex combined with either SCr or CysC), indicating that CysC and SCr are not completely redundant to each other. Further pharmacokinetic evaluation is needed to determine whether SCr or CysC is the better marker of renal elimination of other drugs.

A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

Kidney function assessment for eligibility in clinical cancer trials - Data from the European Organisation for Research and Treatment of Cancer

Pharmacokinetic evaluation of pemetrexed

Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients

Cystatin C as a New Covariate to Predict Renal Elimination of Drugs

Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study

Pretransplant Renal Function Evaluated by Serum Cystatin C Was Associated with Mortality after Liver Transplantation: a Single-Center Experience

Serum Creatinine and Creatinine Clearance for Predicting Plasma Methotrexate Concentrations after High-Dose Methotrexate Chemotherapy for the Treatment for Childhood Lymphoblastic Malignancies

A comparison between serum creatinine and cystatin C-based equations for estimation of graft function

Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma

Proenkephalin Compared to Conventional Methods to Assess Kidney Function in Critically Ill Sepsis Patients

Creatinine Clearance after Cimetidine Administration—Is It Useful in the Monitoring of the Function of Transplanted Kidney?

Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling

Evaluation of Novel Renal Biomarkers with a Cisplatin Model of Kidney Injury: Gender and Dosage Differences

Cystatin C as a Predictor of Renal Function and Methotrexate-Associated Toxicities in Patients With Rheumatoid Arthritis

Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation

Prognostic Prediction of Pemetrexed-Platinum Chemotherapeutic Regimen for NSCLC by Serum Metabolomics.

Estimating kidney function in patients with cancer: A narrative review

Comparison of different estimated glomerular filtration rates for monitoring of kidney function in oncology patients